Size, Share & Industry Analysis, By Product Type (Reagents and Test Consumables, Diagnostic Instruments, Controls and Calibrators, Dedicated Diagnostic Software), By Testing Technology (Immunoassay and Clinical Chemistry, Molecular Diagnostics, Hematology and Coagulation, Microbiology and Other), By Clinical Application (Infectious Diseases, Chronic and Metabolic Diseases, Oncology and Precision Medicine, Women?s Health and Other), By Customer Setting (Hospital Laboratories, Independent Reference Laboratories, Physician Office and Point-of-Care, Public Health and Other), and Global Forecast, 2026-2034
Explore the report section by section.
The global IVD (In Vitro Diagnostic) Testing Market generated USD 16.5 billion in 2025, with an estimated USD 17.8 billion in 2026 and a projected USD 32.0 billion in 2034, representing 7.6% annual growth over 2026–2034.
In vitro diagnostic testing includes clinical assays, analyzers and dedicated consumables that examine patient specimens outside the body. The revenue boundary here follows the narrower defined diagnostic-testing product basket rather than all global IVD spending. Instruments and proprietary reagents used for chemistry, immunoassays, hematology, microbiology and molecular testing are included; unrelated imaging, therapeutic medicines and broad hospital laboratory service billings are excluded. This distinction prevents a diagnostic division total from being presented as the value of this specific basket.
Roche reported CHF 13.8 billion of Diagnostics sales in 2025, while bioM - rieux reported EUR 4.07 billion in consolidated sales and Danaher disclosed USD 9.94 billion for its Diagnostics segment. These corporate figures cover product portfolios broader than the market boundary and serve as indicators of supplier investment rather than additive market components. The recurring economics of test cartridges, calibrators and quality controls mean that a laboratory instrument placement often creates reagent demand over several years.
The World Health Organization reported that 54% of 8.3 million people newly diagnosed with tuberculosis in 2024 received a WHO-recommended rapid test initially, compared with 48% in 2023. Expanding molecular test coverage requires installed systems, trained operators and reliable cartridge distribution. In the United States, Roche received FDA clearance and a CLIA waiver for cobas liat sexually transmitted infection assays in January 2025, allowing testing in decentralized clinical settings with results in about 20 minutes.
Europe is adjusting diagnostic procurement and certification under the In Vitro Diagnostic Regulation, with class C legacy devices required to complete transition by December 2028 if the prescribed conditions are met. The regulatory burden favors manufacturers with established quality systems and a wide validated assay menu. In Asia-Pacific, Sysmex reported fiscal 2026/3 diagnostic reagent sales of JPY 307.9 billion, illustrating the significance of repeat consumables purchasing in high-throughput laboratory networks.
Source: WHO TB diagnosis; Roche annual report; bioM - rieux results.
Revenue includes manufacturer sales of dedicated IVD diagnostic analyzers, assays, reagents, calibrators and consumables used to test human specimens in clinical settings.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Product Type | Reagents and Test Consumables; Diagnostic Instruments; Controls and Calibrators; Dedicated Diagnostic Software |
| By Testing Technology | Immunoassay and Clinical Chemistry; Molecular Diagnostics; Hematology and Coagulation; Microbiology and Other |
| By Clinical Application | Infectious Diseases; Chronic and Metabolic Diseases; Oncology and Precision Medicine; Women’s Health and Other |
| By Customer Setting | Hospital Laboratories; Independent Reference Laboratories; Physician Office and Point-of-Care; Public Health and Other |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; United Kingdom; China; Japan; India; Brazil; South Africa |
| Key Market Players | Roche Diagnostics; Abbott Laboratories; Danaher Corporation; Siemens Healthineers AG; bioM - rieux SA; QuidelOrtho Corporation; Becton, Dickinson and Company; Thermo Fisher Scientific Inc.; Bio-Rad Laboratories Inc.; Sysmex Corporation; Hologic Inc.; QIAGEN N.V.; DiaSorin S.p.A. |
The market covers IVD products and dedicated software sold to perform or support clinical specimen analysis. It counts instruments when sold and reagent, cartridge and control revenue when supplied; it does not add the full fee charged by a hospital or laboratory for a patient test. This is a product-side boundary rather than a comprehensive measurement of clinical laboratory services.
Manufacturer-wide diagnostic revenues from Roche, Danaher and Siemens Healthineers include assays or geographies beyond this specific diagnostic-testing basket. Their reported segment sales therefore provide competitive context but are not added together to construct the market value. The four segmentation axes describe the same revenue once each by product, technology, clinical use and purchasing setting.
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Chronic disease testing and recurrent reagent consumption | High | +3.00% | High | High | High |
| Expansion of rapid molecular diagnostics in community care | High | +2.55% | High | High | Medium |
| Laboratory automation and connected high-throughput analyzers | Medium-High | +2.10% | High | High | Medium |
| Tuberculosis and infectious disease diagnostic coverage | Medium | +1.70% | High | Medium | Medium |
| Companion testing and oncology biomarker adoption | Low-Medium | +1.20% | Medium | High | High |
| Others (quality controls, menu extensions, laboratory consolidation) | Low | +0.90% | Medium | Medium | Low |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Tender pricing and payer reimbursement constraints | High | -1.45% | High | High | High |
| EU IVDR certification and product maintenance costs | Medium-High | -1.10% | High | High | Medium |
| Capital limits on analyzer replacement in smaller laboratories | Medium | -0.75% | High | Medium | Medium |
| Others (reagent supply disruptions, tariffs, staffing shortages) | Low | -0.55% | Medium | Medium | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 7.6% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
Diabetes, cardiovascular disorders and cancer require repeated chemistry, immunoassay and molecular testing rather than a single diagnostic event. Siemens Healthineers reported EUR 4.35 billion of Diagnostics revenue in fiscal 2025, illustrating the scale of routine-testing platforms. Hospital laboratories replenish calibrators and reagents according to patient volumes, while reference laboratories use automated lines to manage large sample batches. Growing screening coverage therefore raises consumables throughput without requiring an equivalent increase in new analyzer placements. U.S. reimbursement for medically necessary testing helps laboratories maintain predictable routine assay orders.
Roche received U.S. FDA 510(k) clearance and a CLIA waiver for cobas liat chlamydia and gonorrhea panels in January 2025. The assays deliver results in about 20 minutes and permit same-visit decisions in urgent-care and community settings. Roche subsequently reported clearance for a Bordetella molecular test in December 2025, with a 15-minute result. These platforms expand testing occasions outside reference laboratories, but each new menu addition also requires clinical validation, staff training and dependable cartridge distribution. Laboratories also evaluate whether rapid positive results can change same-day prescribing decisions.
WHO reported that 4.5 million of 8.3 million people newly diagnosed with tuberculosis in 2024 initially received a recommended rapid diagnostic test. Its 2025 TB guidance adds testing pathways for disease, infection and drug resistance. More frequent molecular confirmation creates demand for extraction reagents, cartridge-based amplification and quality assurance. Public procurement remains sensitive to test cost, especially in high-burden countries, so adoption depends on grants, national budgets and distribution capacity as much as instrument performance.
The European Commission extended IVDR transition deadlines by risk class through Regulation 2024/1860. Class C legacy tests have an endpoint in December 2028 and class B tests in December 2029, subject to conditions including notified-body agreements. Manufacturers must maintain quality systems and technical documentation while laboratories avoid discontinuity of essential assay menus. Certification costs can delay low-volume product launches and encourage suppliers to concentrate development on assays with predictable demand, moderating market expansion in specialized tests.
Public tenders and consolidated hospital purchasing put pressure on the price of each assay, even when testing volume rises. Sysmex disclosed JPY 307.9 billion in reagent sales for fiscal 2026/3 against JPY 103.2 billion for instruments, demonstrating why consumables economics dominate many platforms. Competitive bidding for analyzer placements can be offset by multi-year reagent contracts, while independent laboratories seek high-throughput instruments that reduce labor per result. Tariffs and distribution costs can still erode supplier margins in import-dependent markets.
Sources: WHO Global Tuberculosis Report 2025; Roche Diagnostics; European Commission IVDR; Sysmex; Siemens Healthineers.
Laboratories are integrating chemistry, immunoassay and hematology systems with middleware that monitors calibration, inventory and analyzer uptime. Siemens Healthineers highlighted diagnostics profitability improvements in fiscal 2025 despite limited comparable sales growth. Suppliers can therefore compete through workflow uptime and assay breadth rather than instrument price alone. A single laboratory group may negotiate standardized reagent menus across several hospitals, favoring platforms with reliable cross-site controls and remote technical support. Large clinical laboratory contracts can consequently extend for several budget cycles.
Roche cobas liat received clearance for STI multiplex panels in January 2025, allowing results during a patient visit. Its December 2025 Bordetella assay added another rapid infectious-disease indication. The WHO 2025 tuberculosis handbook also recommends broader use of rapid molecular diagnostics in care pathways. Near-patient molecular platforms reduce transport delays, but clinical utility depends on suitable patient selection and the availability of effective treatment. Cartridge-based menus are likely to gain spending share where same-day decisions are valuable.
Hologic reported fourth-quarter fiscal 2025 Diagnostics revenue of USD 454.1 million, with growth in core molecular diagnostics offset partly by lower COVID-19 assay sales. QuidelOrtho reported USD 2.73 billion of full-year 2025 revenue and provided 2026 guidance of USD 2.7–2.9 billion. These disclosures show how suppliers are replacing pandemic testing volume with broader respiratory, sexual-health and routine clinical assays. Expanded assay menus reduce dependence on a single seasonal pathogen. Hologic reported its gastrointestinal bacterial and expanded bacterial assays received FDA clearance and CE marking.
Sysmex recorded reagent sales of JPY 307.9 billion in fiscal 2026/3, compared with JPY 103.2 billion of instrument revenue. Bio-Rad reported USD 1.56 billion in 2025 Clinical Diagnostics sales, with quality controls and blood typing among its product drivers. Laboratories require regular control materials to maintain test reliability, creating a revenue stream that is less episodic than analyzer capital expenditure. Vendors that protect reagent availability can preserve installed-base loyalty even during hospital budget restrictions. Hospital accreditation requirements make documented lot-to-lot quality consistency especially important.
European IVDR transitional provisions require class C legacy devices to reach conformity by December 2028 and class B devices by December 2029, with intermediate submission deadlines. In September 2025, the FDA formally vacated its earlier laboratory-developed-test final rule following a court decision. These developments create different compliance paths across Europe and the United States. Suppliers entering both markets must tailor evidence packages and commercialization plans, while hospital procurement teams evaluate the continuity of regulated assay availability.
Product revenue is classified into Reagents and Test Consumables, Diagnostic Instruments, Controls and Calibrators, and Dedicated Diagnostic Software. Each assay uses a recurring consumable even when an analyzer is installed for many years. Sysmex fiscal 2026/3 product sales demonstrate the economic weight of consumables relative to instruments.
Reagents and test consumables represented an estimated ~57% of 2025 revenue. Sysmex reported JPY 307.9 billion in fiscal 2026/3 reagent sales, while Bio-Rad described quality controls and blood typing as important clinical diagnostic categories. Cartridge use rises with patient volume, so recurrent purchasing is less sensitive to annual capital budgets than new equipment placements.
Automated chemistry, immunoassay, molecular and hematology analyzers require upfront purchasing or placement contracts. Siemens Healthineers reported Diagnostics revenue of EUR 4.35 billion in fiscal 2025 across a broader business. Laboratories select instruments for throughput, service uptime, menu breadth and the cost of associated reagents, making installation decisions a multiyear commitment.
Independent and manufacturer-specific controls verify test precision, drift and lot consistency. Bio-Rad cited clinical quality controls as a contributor to 2025 diagnostics performance. Calibration is required after service events and reagent changes, which keeps this category linked to regulatory accreditation and instrument usage rather than discretionary equipment replacement.
Laboratory middleware supports result routing, inventory, instrument monitoring and quality tracking. Digital systems can reduce manual transcription and help large hospital groups standardize testing. This category excludes enterprise electronic health records and general-purpose hospital IT, because only diagnostic platform software belongs to the defined revenue pool.
Consumables should remain the leading value category through 2034 as new molecular panels add per-test cartridges and established chemistry analyzers run more tests. Capital spending will fluctuate with replacement cycles, while software and quality controls support continuity and compliance.
The technology axis distinguishes Immunoassay and Clinical Chemistry, Molecular Diagnostics, Hematology and Coagulation, and Microbiology and Other. These are non-overlapping categories assigned according to the primary analytical method used in the assay, regardless of which instrument manufacturer supplies it.
Immunoassay and clinical chemistry represented an estimated ~42% of 2025 revenue. These assays support recurring metabolic, endocrine and cardiac monitoring in hospitals and reference laboratories. Thermo Fisher reported USD 912 million of ImmunoDiagnostics revenue in 2025, although that business also includes products outside this defined technology segment.
PCR and nucleic-acid amplification enable sensitive infectious-disease detection and selected oncology applications. Roche obtained a U.S. CLIA waiver for cobas liat STI assays in January 2025. WHO also identified rapid molecular testing as essential for tuberculosis diagnosis and drug-resistance assessment, creating procurement demand for automated cartridges.
Complete blood counts and coagulation monitoring remain routine in acute and chronic care. Sysmex reported JPY 299.4 billion in hematology revenue for fiscal 2026/3 across its broader diagnostics business. High-throughput analyzer networks encourage reagent standardization, while laboratories assess per-test economics alongside precision and turnaround time.
Culture, organism identification, antimicrobial susceptibility testing and urinalysis complete the technology mix. BioM - rieux reported 4% organic microbiology growth in 2025, despite weakness in China. Clinical laboratories still need culture-based confirmation when rapid panels cannot establish full antimicrobial susceptibility profiles.
Molecular platforms should gain revenue share as same-visit testing and multiplex panels expand. Routine immunoassay and chemistry will retain the largest spending base because repeated chronic disease tests generate high volumes.
Clinical uses are grouped into Infectious Diseases, Chronic and Metabolic Diseases, Oncology and Precision Medicine, and Women’s Health and Other. A diagnostic panel is assigned to the clinical indication for which it is ordered; tests used for several indications are allocated to the dominant ordering pathway.
WHO recorded 8.3 million people newly diagnosed with tuberculosis in 2024, with 54% initially receiving a recommended rapid diagnostic test. Roche added STI and pertussis assays to its cobas liat menu in 2025. Molecular panels help clinicians distinguish pathogens and guide antimicrobial prescribing during the same encounter.
Diabetes and cardiovascular care require repeated HbA1c, chemistry and biomarker measurements. Bio-Rad said blood typing, quality controls and diabetes products were important contributors to its clinical diagnostic business in 2025. Repeat monitoring generates predictable demand for assay kits and calibrators even when the number of installed analyzers changes little.
Tumor biomarker assays increasingly influence targeted therapy decisions, requiring molecular panels or immunohistochemistry. Agilent expanded PD-L1 companion diagnostic indications in February and March 2026. The revenue boundary counts the in-scope assay and reagent products, not the associated cancer medicine or downstream treatment costs.
Sexually transmitted infection panels, prenatal screening and endocrine tests support outpatient diagnostic demand. Hologic reported growth in its BV CV/TV and Panther Fusion assays in fiscal 2025. Expanded testing access can shift volume toward physician offices while complex confirmatory testing remains in accredited laboratories.
Infectious disease testing provides technology-led growth, whereas chronic and metabolic monitoring supplies repeated routine volume. Oncology testing supports higher-value specialty assays but requires payer and regulator acceptance of specific biomarkers.
Purchasers are separated into Hospital Laboratories, Independent Reference Laboratories, Physician Office and Point-of-Care, and Public Health and Other. The classification uses the customer receiving the assay or analyzer, avoiding duplication when a hospital refers a sample to an external laboratory.
Hospital laboratories maintain broad menus for emergency chemistry, hematology, microbiology and molecular testing. Procurement committees weigh analyzer reliability, technical support and reagent contract terms. Large hospital groups can centralize instrument purchasing while retaining satellite specimen collection, concentrating manufacturer revenue in standardized platform families.
Reference laboratories operate automated high-throughput systems and negotiate reagent pricing against large sample volumes. Multiplex molecular testing and specialty oncology assays add complexity to the product mix. Vendors offering compatible instruments, controls and middleware can win long contracts when reference laboratories consolidate facilities or extend regional collection networks.
Roche received FDA clearance and a CLIA waiver for cobas liat STI tests in January 2025, enabling rapid molecular testing in lower-complexity care sites. Same-visit results can reduce patient loss to follow-up, particularly in sexual health clinics. Cartridge pricing and staff training remain important constraints for smaller practices.
WHO-recommended tuberculosis tests are purchased through government, donor and public-health channels. WHO reported that rapid molecular testing initially covered 54% of newly diagnosed TB cases in 2024, leaving room for wider access. Tender procurement emphasizes affordability, supply reliability and evidence of performance across diverse specimen conditions.
Hospital and reference laboratories should continue to dominate value, while near-patient settings add incremental testing occasions. Public-health programs remain dependent on national budgets and procurement schedules.
Regional IVD spending reflects analyzer penetration, reimbursement, infection burden and the regulatory status of diagnostic assays. North America leads by revenue, while Asia-Pacific has large unmet demand for rapid testing.
North America represented an estimated ~39% of 2025 revenue, supported by hospital laboratory networks, established payer codes and frequent chronic disease testing. Roche, Abbott, Danaher and Hologic sell extensive analyzer and reagent portfolios into the United States, where installed instruments generate repeat cartridge and control purchases. Hologic reported USD 454.1 million of fourth-quarter fiscal 2025 Diagnostics revenue and growth in its core U.S. molecular business. Roche received U.S. FDA clearance and a CLIA waiver for cobas liat STI assays in January 2025, widening the setting for molecular testing beyond reference laboratories. In September 2025 the FDA formally vacated its laboratory-developed-test final rule, changing compliance expectations for some laboratories but not removing medical-device requirements for commercial IVD products. Canadian provinces use their own diagnostic purchasing frameworks for hospitals and regional laboratories. The region retains high unit values for complex assays, while group purchasing organizations press suppliers on reagent pricing and instrument-service terms.
Roche received FDA clearance and CLIA waiver for cobas liat chlamydia and gonorrhea panels on 22 January 2025, with results in about 20 minutes. Hologic later reported fiscal 2025 molecular diagnostic growth excluding COVID-19 testing, driven partly by Panther Fusion and women’s health assays. Decentralized clinics can now offer more same-visit testing, although payer contracts and instrument costs still govern uptake. The FDA vacated its LDT final rule in September 2025.
Source: Roche.
Europe combines a large installed base of chemistry and immunoassay analyzers with an evolving risk-based regulatory framework. Roche reported CHF 13.8 billion of global Diagnostics sales in 2025, while Siemens Healthineers generated EUR 4.35 billion of Diagnostics revenue in fiscal 2025. Both companies operate major European development and manufacturing sites and compete for hospital and reference-laboratory contracts. The European Commission extended transition periods under Regulation 2024/1860, with class C legacy tests facing a December 2028 endpoint and class B tests a December 2029 endpoint when conditions are satisfied. These deadlines increase demand for documentation, notified-body review and assay menu rationalization. Germany, France and the United Kingdom have established centralized laboratory networks, while eastern European markets show more uneven molecular platform coverage. Laboratories evaluate supplier continuity carefully because replacing a certified analyzer can require extensive staff retraining and test validation.
Siemens Healthineers reported EUR 4.35 billion in fiscal 2025 Diagnostics sales across its international business, and Germany remains an important European diagnostics development center. Under the EU IVDR, class C legacy products must complete the extended transition by December 2028 if the manufacturer meets specified application and agreement conditions. German laboratories therefore review CE-marked assay availability alongside analyzer uptime and consumable contracts, favoring suppliers with established notified-body pathways.
Source: European Commission.
Asia-Pacific combines large urban hospital laboratories with countries where rapid molecular testing remains unevenly distributed. Sysmex disclosed fiscal 2026/3 sales of JPY 307.9 billion for reagents and JPY 299.4 billion for hematology across its global business, illustrating the importance of recurring laboratory consumables. China has extensive tertiary-hospital automation but price-focused public tenders, while India is expanding district-level molecular and infectious-disease testing. WHO reported that 41% of newly diagnosed tuberculosis cases in its South-East Asia Region initially received a recommended rapid test in 2024, compared with 70% in the Western Pacific Region. The difference creates a clear access gap for affordable cartridge systems and specimen logistics. Japan remains a technologically advanced laboratory market with stringent quality standards, and Australia supports specialty molecular assays through established pathology networks. Lower average test prices constrain regional revenue relative to patient volumes.
WHO found that only 41% of newly diagnosed TB patients in its South-East Asia Region received a recommended rapid test initially in 2024, indicating an access gap across the region. India is expanding decentralized diagnostic capacity through national TB and public laboratory programs, creating demand for cartridge supply, calibration and staff training. Cost-sensitive tenders favor reliable instruments with low per-test consumable prices, particularly in district facilities.
Source: WHO.
Latin American IVD markets depend on a combination of public hospital tenders, private diagnostic chains and imported analyzer technology. Brazil and Mexico have large urban testing networks, while rural regions experience longer sample transport times and fewer molecular instruments. Infectious-disease programs create demand for pathogen detection and surveillance, and chronic disease management sustains routine chemistry testing. Suppliers including Roche, Abbott, bioM - rieux and Sysmex distribute systems through local subsidiaries and channel partners. Currency fluctuations and public procurement cycles affect the timing of instrument replacement, encouraging laboratories to extend the life of installed platforms. Brazilian purchasing groups prioritize predictable reagent shipments when selecting analyzer contracts. Rapid molecular systems can improve turnaround time where transport to centralized laboratories is difficult, but decentralized expansion depends on trained staff, maintenance coverage and sustainable per-test funding. Brazil’s public and private laboratory systems differ in reimbursement and contracting arrangements.
Brazilian public laboratories procure infectious-disease tests through government budgets while private diagnostic networks invest in high-throughput chemistry and molecular platforms. WHO’s 2025 tuberculosis report identifies rapid diagnostic coverage as a major element of national TB control programs. Cartridge availability and predictable service support matter when analyzers operate far from central distribution centers. Currency exposure raises the cost of imported reagents, making long-term supplier contracts important for laboratory budgeting.
Source: WHO.
Middle East and Africa has highly varied diagnostic capacity, from automated Gulf hospital networks to facilities in sub-Saharan Africa that depend on donor-supported infectious-disease programs. WHO recorded substantial differences in recommended rapid tuberculosis test use across its regions during 2024, with coverage limited by instrument placement and specimen access. South Africa has established molecular testing infrastructure, while many smaller national programs must balance reagent cost with electricity, service and workforce constraints. Gulf countries invest in hospital automation and high-acuity testing as specialty care capacity expands. Suppliers with robust cartridge logistics and remote service capability can improve system uptime where engineers are scarce. Public-health purchasers prioritize assays with established WHO recommendations, while private hospitals focus on menu breadth and turnaround times. Regional revenue should rise as rapid molecular testing and chronic disease monitoring reach more facilities, but affordability remains a significant constraint.
WHO reported that rapid molecular tests are central to detecting tuberculosis and rifampicin resistance, with diagnostic coverage still varying substantially among high-burden countries in 2024. South African public laboratories use molecular platforms within national TB programs, creating recurring demand for cartridges and quality controls. Maintenance, transport and supply interruptions can reduce effective instrument capacity even after systems are installed. Procurement planning must therefore account for reagents as well as equipment.
Source: WHO.
IVD competition centers on analyzer installed bases, validated assay menus and recurring consumables. Roche, Abbott, Danaher and Siemens Healthineers supply broad hospital platforms, while bioM - rieux, QuidelOrtho and Hologic focus on defined diagnostic applications. Annual segment revenue figures are broader than the specific diagnostic-testing revenue boundary.
Roche reported CHF 13.8 billion of Diagnostics sales in 2025 and expanded cobas liat molecular testing with STI and Bordetella assays. Abbott competes across clinical chemistry, immunoassay and rapid diagnostics, using large installed analyzer fleets to support ongoing reagent demand. Both face tender pressure on routine tests while seeking higher-value molecular applications.
Siemens Healthineers reported EUR 4.35 billion of fiscal 2025 Diagnostics revenue, while Danaher reported USD 9.94 billion in its Diagnostics segment. Danaher combines Beckman Coulter laboratory platforms with Cepheid molecular testing. Siemens competes on connected workflow and assay menu breadth, with service capability influencing multi-hospital procurement decisions.
bioM - rieux reported EUR 4.07 billion of 2025 revenue and EUR 598 million from BIOFIRE non-respiratory panels. QuidelOrtho reported USD 2.73 billion of 2025 revenue, spanning immunoassay and other testing products. Both companies seek to replace pandemic-related demand with diversified respiratory, gastrointestinal and routine diagnostic menus.
Sysmex disclosed JPY 307.9 billion of reagent sales in fiscal 2026/3, while Bio-Rad recorded USD 1.56 billion of 2025 Clinical Diagnostics sales. Hologic reported fiscal 2025 growth in core molecular testing excluding COVID-19 assays. Their product focus creates competitive strength in hematology, quality control and women’s health respectively.
Procurement departments assess total cost per reportable result, not simply the purchase price of an analyzer. A platform with a broad test menu can reduce maintenance contracts and sample transfers, but proprietary reagent pricing increases dependence on the manufacturer. Large reference laboratories can negotiate discounts because they commit predictable test volumes. Smaller hospitals value responsive local service, stable controls and a user interface that limits training time.
Innovation investment is moving toward molecular multiplexing, laboratory connectivity and specialized oncology tests. Roche’s 2025 cobas liat approvals and Danaher’s Cepheid menu expansion illustrate how established instruments gain new clinical uses without replacing the entire installed base. European IVDR certification increases fixed compliance costs, which may favor suppliers able to spread validation expenses across many assays. Competitive positioning will depend on quality, reimbursement, menu relevance and dependable consumable supply.
February 2026: bioM - rieux announced full-year 2025 sales of EUR 4.07 billion and reported BIOFIRE non-respiratory panel sales of EUR 598 million, up 10% organically. SPOTFIRE sales reached EUR 168 million, an 84% increase, supported by a larger instrument base. The results show continuing demand for multiplex diagnostics beyond pandemic testing. Source
December 2025: Roche announced FDA clearance and CLIA waiver for a cobas liat Bordetella molecular test with results in about 15 minutes. The assay expands the instrument menu into pertussis testing and allows rapid differentiation of related pathogens in near-patient settings. The test complements respiratory pathogen panels already available on the cobas liat instrument and supports same-visit treatment decisions. Source
November 2025: Siemens Healthineers reported fiscal 2025 group revenue of EUR 23.4 billion and comparable Diagnostics growth of 0.4%. Management highlighted improvement in diagnostics operating profitability while preparing its 2026 outlook. The results reflect cost and workflow pressures facing large analyzer suppliers. The company also forecast 5–6% comparable group revenue growth for fiscal 2026, highlighting continued investment despite tariff costs. Source
September 2025: The FDA formally vacated its 2024 laboratory-developed-test final rule following a U.S. district court decision. The change restored the prior regulatory definition and altered compliance planning for laboratories, while commercial IVD medical devices remained subject to applicable device rules. The agency restored its earlier 21 CFR 809.3(a) regulatory text and declined to appeal the court judgment. Source
January 2025: Roche obtained U.S. FDA 510(k) clearance and a CLIA waiver for cobas liat CT/NG and CT/NG/MG assays. The tests return molecular results in about 20 minutes, expanding access to same-visit sexual-health diagnostics in clinics and other decentralized settings. The panels cover chlamydia, gonorrhea and Mycoplasma genitalium using a single sample. Source
June 2024: The European Union adopted Regulation 2024/1860 to extend transitional periods for eligible legacy IVD devices. Manufacturers must satisfy quality-system and notified-body conditions, with later deadlines for lower-risk classes. The change supports test availability while manufacturers complete conformity assessments. Class C devices have a December 2028 transition endpoint, while class B and sterile class A devices extend to December 2029. Source
The defined diagnostic-testing market is forecast to expand from USD 17.8 billion in 2026 to USD 32.0 billion in 2034, corresponding to a 7.6% CAGR as assay consumption and molecular testing rise.
| Forecast Variable | 2025–2026 Evidence | Effect Through 2034 |
|---|---|---|
| Consumables | Sysmex reagent sales JPY 307.9 Bn in FY2026/3 | Repeat tests support stable revenue |
| Molecular access | Roche cobas liat STI clearance January 2025 | More same-visit tests |
| Infection surveillance | WHO rapid TB test use 54% in 2024 | Procurement opportunities |
| EU regulation | Class C IVDR transition to December 2028 | Compliance and product costs |
| Supplier concentration | Roche and Danaher large diagnostics segments | Platform-led reagent contracts |
Recurring reagent purchases should generate more predictable revenue than equipment replacement cycles. Sysmex fiscal 2026/3 sales show a substantially larger reagent category than instrument sales, and Bio-Rad continues to derive clinical diagnostic revenue from quality controls and blood typing. Hospital groups are likely to standardize analyzer fleets to reduce calibration and service complexity. These contracts can strengthen supplier retention but may compress reagent prices when purchasers commit higher test volumes.
Molecular testing is expected to increase its share of the defined basket as multiplex assays expand beyond centralized laboratories. Roche’s cobas liat STI clearance in January 2025 and Bordetella clearance in December 2025 demonstrate how new assays can extend the utility of installed instruments. WHO tuberculosis guidance also creates an evidence base for public procurement of rapid molecular platforms. Commercial growth will depend on whether clinics can sustain cartridge spending and operator training.
Growth between 2026 and 2034 will differ materially among regions because testing coverage and budgets vary. North America retains the largest value pool because reimbursement and automation are established, whereas Asia-Pacific offers greater potential to close rapid-testing access gaps. WHO data show substantially lower initial recommended rapid TB test coverage in South-East Asia than in the Western Pacific during 2024. Public-health procurement can improve coverage, but imported reagent costs and laboratory workforce shortages constrain adoption in lower-income settings.
The European IVDR timetable creates a measurable compliance inflection during 2026–2029. Class C and class B transition deadlines require manufacturers to prioritize documentation and notified-body capacity. Suppliers with large validated menus may gain share if smaller competitors discontinue low-volume assays. Countervailing pressure comes from hospital tenders, reimbursement restrictions and exchange-rate movements, which can reduce average revenue per test even as patient volumes rise.
The coverage includes product-side diagnostic revenue, test technologies, clinical uses and purchasing settings over 2025–2034.
The defined IVD testing product basket generated USD 16.5 billion in 2025 and is estimated at USD 17.8 billion for 2026. Revenue is projected to reach USD 32.0 billion in 2034. These figures refer to the defined product scope, not every clinical laboratory service or all diagnostics sales worldwide.
The IVD (In Vitro Diagnostic) Testing Market is projected to grow at 7.6% annually from 2026 to 2034. Recurrent assay consumption, decentralized molecular tests and automation support demand. Tender pricing, reimbursement limits and European certification costs temper the increase in revenue per test.
Reagents and test consumables represented an estimated ~57% of 2025 revenue. Sysmex reported much higher reagent than instrument sales in fiscal 2026/3, demonstrating the recurring economics of installed diagnostic platforms. Bio-Rad clinical quality controls and analyzer calibration materials require repeat laboratory orders.
Immunoassay and clinical chemistry represented an estimated ~42% of 2025 revenue. These technologies serve high-volume chronic disease monitoring, endocrine testing and emergency chemistry. Molecular diagnostics should grow faster as multiplex panels and near-patient platforms gain new indications.
North America represented an estimated ~39% of worldwide revenue in 2025. U.S. hospital networks, reference laboratories and established reimbursement support large assay volumes. Europe has extensive automation, while Asia-Pacific has substantial unmet need for rapid molecular testing.
Yes. Roche received FDA clearance and a CLIA waiver for cobas liat STI panels in January 2025, enabling results in about 20 minutes in eligible care settings. The platform also received a pertussis assay clearance in December 2025, expanding its clinical menu.
IVD reagents are products sold to laboratories or clinicians to perform tests, while laboratory services are the fees charged for interpreting and delivering patient results. This market counts reagent, instrument and dedicated diagnostic product revenue rather than adding downstream testing service billings.
The EU IVDR requires risk-based conformity assessment and documented quality systems. Regulation 2024/1860 extended eligible legacy-device transition periods, including to December 2028 for class C and December 2029 for class B devices. Class C manufacturers faced a 2026 notified-body agreement deadline to qualify for the extended transition.
Roche, Abbott, Danaher, Siemens Healthineers, bioM - rieux, QuidelOrtho, BD, Thermo Fisher, Bio-Rad, Sysmex and Hologic are established diagnostic suppliers. Their portfolios span different technologies, so total company or division sales should not be interpreted as this narrower market size.
Consolidated hospital purchasing, public tenders, reimbursement restrictions and reagent supply costs affect prices. Laboratories compare total cost per reportable result and service uptime rather than instrument prices alone. Certification and validation requirements can also raise the cost of maintaining low-volume assays.
The market is forecast at USD 32.0 billion in 2034, with growth supported by molecular menu extensions and recurring consumables. WHO tuberculosis guidance and new Roche cobas liat assays illustrate clinical expansion. Public procurement budgets and EU regulatory deadlines remain important constraints.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.